Antimicrobial Therapeutics Market size to grow by USD 51.4 billion from 2022 to 2027, Driven by initiatives from government agencies in the pharmaceutical industry
Pharmaceuticals

Antimicrobial Therapeutics Market size to grow by USD 51.4 billion from 2022 to 2027, Driven by initiatives from government agencies in the pharmaceutical industry

Staff Reporter 1243 Views 0 Comments

NEW YORK, April 10, 2023 /PRNewswire/ — The antimicrobial therapeutics market size is forecasted to increase by USD 51.4 billion from 2022 to 2027, at a CAGR of 5.63%, according to the recent market study by Technavio. The growth of the market will be driven by the recent drug approvals and robust pipeline, initiatives from government agencies in the pharmaceutical industry, and rising awareness about microbial diseases. Technavio offers an up-to-date analysis of the current global market scenario and the overall market environment. View a Sample Report 

Technavio has announced its latest market research report titled Global Antimicrobial Therapeutics Market 2023-2027

Technavio has announced its latest market research report titled Global Antimicrobial Therapeutics Market 2023-2027

Technavio categorizes the global antimicrobial therapeutics market Vendor Analysis:

The global antimicrobial therapeutics market is fragmented, with the presence of numerous small-scale, medium-scale, and large-scale manufacturers. Technavio has extensively analyzed 15 major vendors, including AbbVie Inc., Astellas Pharma Inc., Bavarian Nordic AS, Biocidium Biopharmaceuticals Inc., Bristol Myers Squibb Co., Cadila Pharmaceuticals Ltd., CSL Ltd., Emergent BioSolutions Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Inovio Pharmaceuticals Inc., Johnson and Johnson Services Inc., Merck and Co. Inc., Mitsubishi Tanabe Pharma Corp., Novartis AG, Novavax Inc., Pfizer Inc., Sanofi SA, and Wockhardt Ltd.

Vendor Offerings –

  • AbbVie Inc. – The company offers azactam injection, which is used to treat symptoms of bacterial infections that occur in the blood and urinary tract.
  • Astellas Pharma Inc. – The company offers a fidaxomicin antimicrobial drug that is used to treat clostridium difficile-associated diarrhea germ.
  • Bavarian Nordic AS – The company offers an antimicrobial drug that is used to treat urinary tract infections caused by certain bacteria.

Charts & data tables about market and segment sizes for a historic period (2017-2021) and forecast period (2023-2027) have been covered in this report. Download the Sample Report

Key Benefits for Industry Players & Stakeholders – 

  • The report offers information on the criticality of vendor inputs, including R&D, CAPEX, and technology.
  • It also provides detailed analyses of the market’s competitive landscape and vendors’ product offerings.
  • The report also provides a qualitative and quantitative analysis of vendors to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Expand operations in the future – To get requisite details, ask for a custom report.

Market Segmentation:

This report extensively covers market segmentation by application (antiviral, antibacterial, antifungal, and antiparasitic), end-user (pharmacies, hospitals and clinics, and research and academic institutes), and geography (North America, Europe, Asia, and the Rest of the World (ROW)). 

  • The market share growth by the antiviral segment will be significant for the market growth during the forecast period. The segment is driven by the rising predominance of viral diseases such as flu, hepatitis, coronavirus, and HIV/AIDS. Therefore, during the forecast period, the global outbreak of viral diseases is anticipated to contribute to market expansion. 

Get a holistic overview of the market from industry experts to evaluate and develop growth strategies. Download the Sample

Market Dynamics:

Key Drivers:

  • Initiatives from government agencies in the pharmaceutical industry will notably drive the demand for antimicrobial therapeutics during the forecast period. 
  • In many developed nations, such as the US, Canada, the UK, Germany, France, Australia, and Japan, government insurance programs for medicines aid in the treatment of patients with microbial infections.
  • The eradication of infectious diseases caused by microorganisms requires substantial funding from both public and private sources. Due to their inclusion on the WHO’s list of diseases that must be eradicated, antimicrobial diseases are receiving more funding.
  • For instance, the Infectious Disease Research Institute received a grant of 15 million dollars from the Bill and Melinda Gates Foundation to develop a vaccine against leishmaniasis. Over the forecast period, such initiatives are anticipated to drive the market in focus.
  • In an effort to eradicate microbial diseases, a number of government and non-governmental organizations, such as the World Bank Group and the Bill and Melinda Gates Foundation, are launching various awareness campaigns and providing funding.

Major Trends:

  • The growth in disease diagnostic modalities is a new trend in the global antimicrobial therapeutics market. 
  • In recent years, diagnostics and biomarkers, which are measurable cellular, biochemical, or molecular alterations in biological samples that indicate any biological, pathogenic, or therapeutic response, have been introduced.
  • Many companies are focusing on the creation of proof-of-concept products that have the potential to significantly shorten the duration of diagnostic procedures while still ensuring high levels of patient compliance.
  • Simple point-of-care (POC) tests and several promising laboratory-based viral load technologies will soon be widely available.
  • Therefore, disease diagnostic modalities are anticipated to lead to market expansion during the forecast period.

Key Challenges:

  • The increased availability of generic drugs is a key challenge that may impede the global antimicrobial therapeutics market growth during the forecast period.
  • Vendors are focusing on manufacturing low-cost alternatives to approved medicines as a result of patent expiration and loss of exclusivity.
  • Generic medicines, vaccines, antibiotics, and biosimilars also come at a lower cost than brand-name medicines.
  • For instance, for the treatment of chronic hepatitis C, Gilead Sciences Inc. (Gilead) plans to offer authorized generics of Epclusa and Harvoni for USD 24,000, which is nearly 75% less than the cost of brand-name medications.
  • Lexiva is a preventative medication developed by ViiV Healthcare, a Pfizer and GlaxoSmithKline joint venture. The generic Lexiva is currently available for purchase in the US through Mylan Inc. (Mylan).

To get detailed insights, buy the report 

What are the key data covered in this Antimicrobial Therapeutics Market report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the antimicrobial therapeutics market between 2023 and 2027
  • Precise estimation of the size of the antimicrobial therapeutics market and its contribution to the parent market
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the antimicrobial therapeutics market across North America, Europe, Asia, and the Rest of the World (ROW)
  • A thorough analysis of the market’s competitive landscape and detailed information about vendors
  • Comprehensive analysis of factors that will challenge the growth of antimicrobial therapeutics market vendors

Related Reports:

The Alzheimer’s disease therapeutics market is estimated to grow at a CAGR of 8.91% between 2022 and 2027. The size of the market is forecast to increase by USD 4,391.9 million. This report extensively covers market segmentation by drug class (cholinesterase inhibitors, n-methyl-d-aspartate receptor antagonist, and others), distribution channel (hospital pharmacy, retail pharmacy, and e-commerce pharmacy), and geography (North America, Europe, Asia, and Rest of World). The increasing awareness of Alzheimer’s disease is notably driving market growth.

The gastrointestinal stromal tumors therapeutics market size is expected to increase by USD 1.08 billion from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 5.97%. The report extensively covers market segmentation by route of administration (oral and parenteral) and geography (North America, Europe, Asia, and the Rest of the World (ROW)). The growing geriatric population is one of the factors driving the gastrointestinal stromal tumors therapeutics (GIST) market growth.

Gain instant access to 17,000+ market research reports. 
Technavio’s SUBSCRIPTION platform

Antimicrobial Therapeutics Market Scope

Report Coverage

Details

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 5.63%

Market growth 2023-2027

USD 51.4 billion

Market structure

Fragmented

YoY growth 2022-2023 (%)

5.22

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 38%

Key countries

US, Germany, France, China, and Japan

Competitive landscape

Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

AbbVie Inc., Astellas Pharma Inc., Bavarian Nordic AS, Biocidium Biopharmaceuticals Inc., Bristol Myers Squibb Co., Cadila Pharmaceuticals Ltd., CSL Ltd., Emergent BioSolutions Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Inovio Pharmaceuticals Inc., Johnson and Johnson Services Inc., Merck and Co. Inc., Mitsubishi Tanabe Pharma Corp., Novartis AG, Novavax Inc., Pfizer Inc., Sanofi SA, and Wockhardt Ltd.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Browse for Technavio’s Health Care Market Reports

Table of contents

1 Executive Summary

  • 1.1 Market overview 
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Application
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by End-user
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem 
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition 
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis 
    • Exhibit 13: Market segments
  • 3.4 Market outlook: Forecast for 2022-2027
    • Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
    • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

  • 4.1 Global antimicrobial therapeutics market 2017 – 2021
    • Exhibit 18: Historic Market Size – Data Table on Global antimicrobial therapeutics market 2017 – 2021 ($ billion)
  • 4.2 Application Segment Analysis 2017 – 2021
    • Exhibit 19: Historic Market Size – Application Segment 2017 – 2021 ($ billion)
  • 4.3 End-user Segment Analysis 2017 – 2021
    • Exhibit 20: Historic Market Size – End-user Segment 2017 – 2021 ($ billion)
  • 4.4 Geography Segment Analysis 2017 – 2021
    • Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ billion)
  • 4.5 Country Segment Analysis 2017 – 2021
    • Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ billion)

5 Five Forces Analysis

  • 5.1 Five forces summary 
    • Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
  • 5.2 Bargaining power of buyers 
    • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
  • 5.3 Bargaining power of suppliers 
    • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
  • 5.4 Threat of new entrants 
    • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
  • 5.5 Threat of substitutes 
    • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
  • 5.6 Threat of rivalry 
    • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
  • 5.7 Market condition 
    • Exhibit 29: Chart on Market condition – Five forces 2022 and 2027

6 Market Segmentation by Application

  • 6.1 Market segments 
    • Exhibit 30: Chart on Application – Market share 2022-2027 (%)
    • Exhibit 31: Data Table on Application – Market share 2022-2027 (%)
  • 6.2 Comparison by Application 
    • Exhibit 32: Chart on Comparison by Application
    • Exhibit 33: Data Table on Comparison by Application
  • 6.3 Antiviral – Market size and forecast 2022-2027
    • Exhibit 34: Chart on Antiviral – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 35: Data Table on Antiviral – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 36: Chart on Antiviral – Year-over-year growth 2022-2027 (%)
    • Exhibit 37: Data Table on Antiviral – Year-over-year growth 2022-2027 (%)
  • 6.4 Antibacterial – Market size and forecast 2022-2027
    • Exhibit 38: Chart on Antibacterial – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 39: Data Table on Antibacterial – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 40: Chart on Antibacterial – Year-over-year growth 2022-2027 (%)
    • Exhibit 41: Data Table on Antibacterial – Year-over-year growth 2022-2027 (%)
  • 6.5 Antifungal – Market size and forecast 2022-2027
    • Exhibit 42: Chart on Antifungal – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 43: Data Table on Antifungal – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 44: Chart on Antifungal – Year-over-year growth 2022-2027 (%)
    • Exhibit 45: Data Table on Antifungal – Year-over-year growth 2022-2027 (%)
  • 6.6 Antiparasitic – Market size and forecast 2022-2027
    • Exhibit 46: Chart on Antiparasitic – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 47: Data Table on Antiparasitic – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 48: Chart on Antiparasitic – Year-over-year growth 2022-2027 (%)
    • Exhibit 49: Data Table on Antiparasitic – Year-over-year growth 2022-2027 (%)
  • 6.7 Market opportunity by Application 
    • Exhibit 50: Market opportunity by Application ($ billion)
    • Exhibit 51: Data Table on Market opportunity by Application ($ billion)

7 Market Segmentation by End-user

  • 7.1 Market segments 
    • Exhibit 52: Chart on End-user – Market share 2022-2027 (%)
    • Exhibit 53: Data Table on End-user – Market share 2022-2027 (%)
  • 7.2 Comparison by End-user 
    • Exhibit 54: Chart on Comparison by End-user
    • Exhibit 55: Data Table on Comparison by End-user
  • 7.3 Pharmacies – Market size and forecast 2022-2027
    • Exhibit 56: Chart on Pharmacies – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 57: Data Table on Pharmacies – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 58: Chart on Pharmacies – Year-over-year growth 2022-2027 (%)
    • Exhibit 59: Data Table on Pharmacies – Year-over-year growth 2022-2027 (%)
  • 7.4 Hospitals and clinics – Market size and forecast 2022-2027 
    • Exhibit 60: Chart on Hospitals and clinics – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 61: Data Table on Hospitals and clinics – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 62: Chart on Hospitals and clinics – Year-over-year growth 2022-2027 (%)
    • Exhibit 63: Data Table on Hospitals and clinics – Year-over-year growth 2022-2027 (%)
  • 7.5 Research and academic institutes – Market size and forecast 2022-2027 
    • Exhibit 64: Chart on Research and academic institutes – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 65: Data Table on Research and academic institutes – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 66: Chart on Research and academic institutes – Year-over-year growth 2022-2027 (%)
    • Exhibit 67: Data Table on Research and academic institutes – Year-over-year growth 2022-2027 (%)
  • 7.6 Market opportunity by End-user 
    • Exhibit 68: Market opportunity by End-user ($ billion)
    • Exhibit 69: Data Table on Market opportunity by End-user ($ billion)

8 Customer Landscape

  • 8.1 Customer landscape overview 
    • Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

  • 9.1 Geographic segmentation 
    • Exhibit 71: Chart on Market share by geography 2022-2027 (%)
    • Exhibit 72: Data Table on Market share by geography 2022-2027 (%)
  • 9.2 Geographic comparison 
    • Exhibit 73: Chart on Geographic comparison
    • Exhibit 74: Data Table on Geographic comparison
  • 9.3 North America – Market size and forecast 2022-2027
    • Exhibit 75: Chart on North America – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 76: Data Table on North America – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 77: Chart on North America – Year-over-year growth 2022-2027 (%)
    • Exhibit 78: Data Table on North America – Year-over-year growth 2022-2027 (%)
  • 9.4 Europe – Market size and forecast 2022-2027
    • Exhibit 79: Chart on Europe – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 80: Data Table on Europe – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 81: Chart on Europe – Year-over-year growth 2022-2027 (%)
    • Exhibit 82: Data Table on Europe – Year-over-year growth 2022-2027 (%)
  • 9.5 Asia – Market size and forecast 2022-2027
    • Exhibit 83: Chart on Asia – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 84: Data Table on Asia – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 85: Chart on Asia – Year-over-year growth 2022-2027 (%)
    • Exhibit 86: Data Table on Asia – Year-over-year growth 2022-2027 (%)
  • 9.6 Rest of World (ROW) – Market size and forecast 2022-2027 
    • Exhibit 87: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 88: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 89: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
    • Exhibit 90: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
  • 9.7 US – Market size and forecast 2022-2027
    • Exhibit 91: Chart on US – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 92: Data Table on US – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 93: Chart on US – Year-over-year growth 2022-2027 (%)
    • Exhibit 94: Data Table on US – Year-over-year growth 2022-2027 (%)
  • 9.8 China – Market size and forecast 2022-2027
    • Exhibit 95: Chart on China – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 96: Data Table on China – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 97: Chart on China – Year-over-year growth 2022-2027 (%)
    • Exhibit 98: Data Table on China – Year-over-year growth 2022-2027 (%)
  • 9.9 Germany – Market size and forecast 2022-2027
    • Exhibit 99: Chart on Germany – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 100: Data Table on Germany – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 101: Chart on Germany – Year-over-year growth 2022-2027 (%)
    • Exhibit 102: Data Table on Germany – Year-over-year growth 2022-2027 (%)
  • 9.10 France – Market size and forecast 2022-2027
    • Exhibit 103: Chart on France – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 104: Data Table on France – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 105: Chart on France – Year-over-year growth 2022-2027 (%)
    • Exhibit 106: Data Table on France – Year-over-year growth 2022-2027 (%)
  • 9.11 Japan – Market size and forecast 2022-2027
    • Exhibit 107: Chart on Japan – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 108: Data Table on Japan – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 109: Chart on Japan – Year-over-year growth 2022-2027 (%)
    • Exhibit 110: Data Table on Japan – Year-over-year growth 2022-2027 (%)
  • 9.12 Market opportunity by geography 
    • Exhibit 111: Market opportunity by geography ($ billion)
    • Exhibit 112: Data Tables on Market opportunity by geography ($ billion)

10 Drivers, Challenges, and Trends

  • 10.3 Impact of drivers and challenges 
    • Exhibit 113: Impact of drivers and challenges in 2022 and 2027

11 Vendor Landscape

  • 11.2 Vendor landscape 
    • Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
  • 11.3 Landscape disruption 
    • Exhibit 115: Overview on factors of disruption
  • 11.4 Industry risks 
    • Exhibit 116: Impact of key risks on business

12 Vendor Analysis

  • 12.1 Vendors covered 
    • Exhibit 117: Vendors covered
  • 12.2 Market positioning of vendors 
    • Exhibit 118: Matrix on vendor position and classification
  • 12.3 AbbVie Inc. 
    • Exhibit 119: AbbVie Inc. – Overview
    • Exhibit 120: AbbVie Inc. – Product / Service
    • Exhibit 121: AbbVie Inc. – Key news
    • Exhibit 122: AbbVie Inc. – Key offerings
  • 12.4 Astellas Pharma Inc. 
    • Exhibit 123: Astellas Pharma Inc. – Overview
    • Exhibit 124: Astellas Pharma Inc. – Product / Service
    • Exhibit 125: Astellas Pharma Inc. – Key news
    • Exhibit 126: Astellas Pharma Inc. – Key offerings
  • 12.5 Bavarian Nordic AS 
    • Exhibit 127: Bavarian Nordic AS – Overview
    • Exhibit 128: Bavarian Nordic AS – Product / Service
    • Exhibit 129: Bavarian Nordic AS – Key offerings
  • 12.6 Biocidium Biopharmaceuticals Inc. 
    • Exhibit 130: Biocidium Biopharmaceuticals Inc. – Overview
    • Exhibit 131: Biocidium Biopharmaceuticals Inc. – Product / Service
    • Exhibit 132: Biocidium Biopharmaceuticals Inc. – Key offerings
  • 12.7 Bristol Myers Squibb Co. 
    • Exhibit 133: Bristol Myers Squibb Co. – Overview
    • Exhibit 134: Bristol Myers Squibb Co. – Product / Service
    • Exhibit 135: Bristol Myers Squibb Co. – Key news
    • Exhibit 136: Bristol Myers Squibb Co. – Key offerings
  • 12.8 Cadila Pharmaceuticals Ltd. 
    • Exhibit 137: Cadila Pharmaceuticals Ltd. – Overview
    • Exhibit 138: Cadila Pharmaceuticals Ltd. – Product / Service
    • Exhibit 139: Cadila Pharmaceuticals Ltd. – Key offerings
  • 12.9 CSL Ltd. 
    • Exhibit 140: CSL Ltd. – Overview
    • Exhibit 141: CSL Ltd. – Business segments
    • Exhibit 142: CSL Ltd. – Key news
    • Exhibit 143: CSL Ltd. – Key offerings
    • Exhibit 144: CSL Ltd. – Segment focus
  • 12.10 F. Hoffmann La Roche Ltd. 
    • Exhibit 145: F. Hoffmann La Roche Ltd. – Overview
    • Exhibit 146: F. Hoffmann La Roche Ltd. – Business segments
    • Exhibit 147: F. Hoffmann La Roche Ltd. – Key news
    • Exhibit 148: F. Hoffmann La Roche Ltd. – Key offerings
    • Exhibit 149: F. Hoffmann La Roche Ltd. – Segment focus
  • 12.11 Gilead Sciences Inc. 
    • Exhibit 150: Gilead Sciences Inc. – Overview
    • Exhibit 151: Gilead Sciences Inc. – Product / Service
    • Exhibit 152: Gilead Sciences Inc. – Key news
    • Exhibit 153: Gilead Sciences Inc. – Key offerings
  • 12.12 GlaxoSmithKline Plc 
    • Exhibit 154: GlaxoSmithKline Plc – Overview
    • Exhibit 155: GlaxoSmithKline Plc – Business segments
    • Exhibit 156: GlaxoSmithKline Plc – Key news
    • Exhibit 157: GlaxoSmithKline Plc – Key offerings
    • Exhibit 158: GlaxoSmithKline Plc – Segment focus
  • 12.13 Johnson and Johnson Services Inc.
    • Exhibit 159: Johnson and Johnson Services Inc. – Overview
    • Exhibit 160: Johnson and Johnson Services Inc. – Business segments
    • Exhibit 161: Johnson and Johnson Services Inc. – Key news
    • Exhibit 162: Johnson and Johnson Services Inc. – Key offerings
    • Exhibit 163: Johnson and Johnson Services Inc. – Segment focus
  • 12.14 Merck and Co. Inc. 
    • Exhibit 164: Merck and Co. Inc. – Overview
    • Exhibit 165: Merck and Co. Inc. – Business segments
    • Exhibit 166: Merck and Co. Inc. – Key news
    • Exhibit 167: Merck and Co. Inc. – Key offerings
    • Exhibit 168: Merck and Co. Inc. – Segment focus
  • 12.15 Novartis AG 
    • Exhibit 169: Novartis AG – Overview
    • Exhibit 170: Novartis AG – Business segments
    • Exhibit 171: Novartis AG – Key offerings
    • Exhibit 172: Novartis AG – Segment focus
  • 12.16 Pfizer Inc. 
    • Exhibit 173: Pfizer Inc. – Overview
    • Exhibit 174: Pfizer Inc. – Product / Service
    • Exhibit 175: Pfizer Inc. – Key news
    • Exhibit 176: Pfizer Inc. – Key offerings
  • 12.17 Sanofi SA 
    • Exhibit 177: Sanofi SA – Overview
    • Exhibit 178: Sanofi SA – Business segments
    • Exhibit 179: Sanofi SA – Key news
    • Exhibit 180: Sanofi SA – Key offerings
    • Exhibit 181: Sanofi SA – Segment focus

13 Appendix

  • 13.1 Scope of the report 
  • 13.2 Inclusions and exclusions checklist
    • Exhibit 182: Inclusions checklist
    • Exhibit 183: Exclusions checklist
  • 13.3 Currency conversion rates for US$ 
    • Exhibit 184: Currency conversion rates for US$
  • 13.4 Research methodology 
    • Exhibit 185: Research methodology
    • Exhibit 186: Validation techniques employed for market sizing
    • Exhibit 187: Information sources
  • 13.5 List of abbreviations 
    • Exhibit 188: List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio

No Byline Policy

Editorial Guidelines

Corrections Policy

Source

Leave a Reply